dickson: un commission on life-saving commodities for women and children

7/28/2019 Dickson: UN Commission on Life-Saving Commodities for Women and Children

1/19

UN Commission on Life-Saving

Commodities for Women and

Children


2/19

Commission on Information

and Accountability

WHO

Commission on Life Saving

Commodities for Women and Children

UNICEF and UNFPA

Commission ChairsGoodluck Jonathan, President, Nigeria

Jens Stoltenberg, Prime Minister , Norway

Commission ChairsKikwete, President of Tanzania

Harper, Prime Minister of Canada


3/19

3

20 Commissioners

Michael Anderson, Director-General for Policy and Global Programmes, DFID

H.E. Zainab Hawa Bangura, Minister of Health and Sanitation, Sierra Leone

MK Bhan, Secretary to the Government of India Department of Biotechnology

Heather Bresch, CEO, Mylan Inc.

Dan Brutto, President, UPS International

Ray Chambers, UN Secretary-General's Special Envoy for Malaria

Gary Cohen, Executive Vice President, Becton Dickson

Bob Collymore, Chief Executive Officer, Safaricom

Jamie Cooper-Hohn, President and CEO, Children's Investment Fund Foundation

Christopher Elias, President for Global Development, Bill and Melinda Gates Foundation

Kenneth C. Frazier, President and CEO, Merck

Julio Frenk, Chair, Partnership for Maternal, Newborn and Child Health

Teguest Guerma, Director General, AMREFPer Heggenes, CEO, IKEA Foundation

Robert Lee, President, Shanghai Fosun Pharmaceutical Development Co., Ltd.

Hassan Mshinda, Director General, Tanzania Commission for Science and Technology

Agns Saint-Raymond, Head of Human

Medicines Special Areas, European Medicines Agency

Rajiv Shah, Administrator, USAID

Jasmine Whitbread, Chief Executive Officer, Save the Children International

Sir Andrew Witty, Chief Executive Officer, GlaxoSmithKline


4/19

Objectives

1. Identify opportunities to increase the production, supply and

use of affordable, high-quality, high-impact commodities for

womens and childrens health, through shaping the market,strengthening the quality of local production capacity, promoting innovative

technologies and new product development ..

2. Propose innovative strategies to support high-burden countries

to rapidly increase access to overlooked commoditiesthroughproven, private and public sector market shaping interventions.

3. Recommend strategies to raise awareness of and demand for

these life-saving commodities among health care providers and end-users.


5/19

5

Three criteria were established

for identifying a list of underutilized,

life-saving commodities

1. High-impact,

effective commodities

In general, high-impact

commodities are those

medicines, medical

devices and health

supplies that effectively

address avoidable causes

of death and disease

among children andwomen during

pregnancy, childbirth

and childhood.

2. Inadequate funding

Inadequate funding means the

commodity lacks the monetary

support that would allow a

rapid increase in its distribution

and use. Selected commodities,

therefore, are not funded by

existing mechanisms, such as

The Global Fund to Fight AIDS,

Tuberculosis and Malaria, and

GAVI.

3. Untapped potential

Innovation and rapid

increases in product

development and market

opportunities (including the

potential for better

formulations, price reduction

and improved stability of

supply) could rapidly

improve the affordability,

availability and use of

selected medicines, medical

devices and supplies.


6/19

6

13 Life-Saving Commodities

RMNCH Continuum of Care Commodity Usage

Reproductive health Female Condoms Family planning/Contraception

Implants Family planning/Contraception

Emergency Contraception Family planning/Contraception

Maternal Health Oxytocin Post-Partum Hemorrhage

Misoprostol Post-Partum Hemorrhage

Magnesium sulfate Eclampsia and Severe Pre-

Eclamsia/Toxemia of Pregnancy

Newborn Health Injectable antibiotics Newborn Sepsis

Antenatal Corticosteroid (ANCS) Respiratory Distress Syndromefor preterm babies

Chlorhexidine Newborn Cord Care

Resuscitation Equipment Newborn Asphyxia

Child Health Amoxicillin Pneumonia

Oral Rehydration Salts (ORS) Diarrhea

Zinc Diarrhea
http://www.everywomaneverychild.org/component/content/article/1-about/299-female-condoms-product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/300-implants--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/301-emergency-contraception-product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/302-oxytocin--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/303-misoprostol--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/304-magnesium-sulfate-mgso4--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/316-injectable-antibiotics-for-newborn-sepsis--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/307-antenatal-corticosteroids--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/308-chlorhexidine-chx--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/308-chlorhexidine-chx--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/309-newborn-resuscitation-devices--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/305-amoxicillin--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/306-oral-rehydration-salts-ors--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/307-antenatal-corticosteroids--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/298-zinc-product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/308-chlorhexidine-chx--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/308-chlorhexidine-chx--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/298-zinc-product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/307-antenatal-corticosteroids--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/306-oral-rehydration-salts-ors--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/305-amoxicillin--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/309-newborn-resuscitation-devices--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/308-chlorhexidine-chx--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/308-chlorhexidine-chx--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/307-antenatal-corticosteroids--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/316-injectable-antibiotics-for-newborn-sepsis--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/316-injectable-antibiotics-for-newborn-sepsis--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/304-magnesium-sulfate-mgso4--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/304-magnesium-sulfate-mgso4--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/303-misoprostol--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/303-misoprostol--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/302-oxytocin--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/302-oxytocin--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/301-emergency-contraception-product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/301-emergency-contraception-product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/300-implants--product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/299-female-condoms-product-profile-http://www.everywomaneverychild.org/component/content/article/1-about/299-female-condoms-product-profile-


7/19

Three work streams of the

Commissions Working Group

7


8/19

Regulatory challenges- Many developing countries suffer from inadequateregulatory capacity that leads to delayed registration of essential medical

commodities, low quality medical commodities in the marketplace, and inefficiencies

that drive manufacturers away.

Market failures - A market trap is a vicious cycle in which manufacturers expect

that investments in certain products will not result in large sales and profit, so existingmanufacturers have no incentive to improve poor quality products, and new

manufacturers have no incentive to bring new products to market.

User supply and demand challenges- Examples include: low demand for theproduct by prescribers and patients, local delivery and distribution break-downs at or

near the patient/caregiver level, and incorrect prescription and use.

Opportunties include: innovative approaches to product formulation, packaging

and/or delivery devices, and harnessing social media and mobile technology to

promote demand, proper use, and manage supply bottlenecks.

8

Cross-cutting barriers


9/19

Recommendations in

3 Strategic Areas

Improved markets for life-saving commodities

1. Shaping global markets

2. Shaping local delivery markets

3. Innovative Financing

4. Quality strengthening

5. Regulation efficiency

Improved national delivery of life-saving commodities

6. Supply and awareness

7. Demand and awareness

8. Reaching women and children9. Performance and accountability

Improved integration of the private sector and consumer needs

10. Product innovation

9


10/19

Implementation

23 working groups (13 commodities + 10

recommendations)

Technical experts engage for change at the globallevel

10


11/19

UNCoLSC

WorkingGroups

&

Conveners

11

22 Working Groups Conveners

Cross-cutting areas

1. Shaping global market CHAI, DFID

2. Shapi ng del ivery markets CHAI, Gov. of Ni geri a

3. Innovative Financing World Bank, Norway

4. Quality strengthening WHO, Gov. of Nigeria

5. Regulation efficiency WHO, Gov. of Nigeria

6. Supply and awareness USAID, UNFPA

7. Demand and awareness USAID, Gov. of Tanzani a

8. Reaching women and children Gov. of Uganda, Save the Children

9. Performance and accountability AMREF, m-Health Alliance

10. Product innovation PATH

Commodity-specific areas

Oxytocin, MgSO4 USAID

Misoprostol, Female Condoms UNFPA

Injectable antibiotics SNL

Antenatal Corticosteriods Save the Children, BMGF

Chlorhexidine PATH

Newborn resusci tation Equi pment USAID

Amoxicil l in UNICEF, CHAI

ORS, zinc CHAI, UNICEF

Female condoms UNFPA

Contraceptive implants BMGF, DFID

Emergency contraception WHO


12/19

October 2012, Abuja:

8 Pathfinder Countries

1. DRC

2. Ethiopia

3. Malawi

4. Nigeria

5. Senegal

6. Sierra Leone

7. Tanzania

8. Uganda

12

16 October 2012: Ministers of Health sign Abuja Declaration


13/19

National leadership is

the key element

13

The goal of engagement at the country level is to:

Sharpen existing RMNCH plans to ensure alignment

between interventions/ strategies and the local situation.

Identify and prioritize key high-impact interventions for

scale-up.

Develop a concept note that outlines key catalytic, high-

impact, cost-effective interventions; existing funding and

funding gaps.


14/19

Country planning for 8 pathfinder countries

The Nigeria example

Burden ofdisease

Priorityinterventions

(LiST)

Prioritycommodities

AIM: to rapidly increase access to and use of

ORS, zinc , amoxicillin DT and CHX

Focus on local market shaping and on access/demand

f d l i f


15/19

Process for Landscape Analysis of

RMNCH Programmes(Addressing the goals of EWEC, A Promised Renewed, and UNCoLSC)


16/19

2012, September 26

Goodluck Jonathan, President, Nigeria and Jens Stoltenberg, Prime Minister,

Norway handover the Commission Report to the UNSG

2012 , October 16, Abuja meeting

President Goodluck Jonathan hosts a Commission meeting in Abuja

countries sign the Ministerial Communique

2012 Nov onwards - Planning and action

Country planning in 8 pathfinder countries

Implementation for the 13 commodity and 10 recommendation groups

2011, September :

UN SG calls Exec Directors of UNFPA and UNICEF to organize a UN Commission

on this issue

2012 , March UN Commission in launched

Implementation plan endorsed + funding is announced


17/19

RMNCH Fund

Purpose: Mobilize catalytic funding for national

RMNCH strategies

Hosted by UNFPA

Secretariat housed at UNICEF, with staff from

WHO, UNFPA, UNICEF

Secretariat managed by Pascal Bijleveld

Steering Committee to advise donors, based on

analysis by Commission working groups, H4+,

IHP+ etc.17


18/19

Next stepsApril 2013

Finalization by Government and country stakeholders of

sharpened national RMNCH plans

Steering Committee meeting to review country engagement

progress and strategy for the coming year

Harmonizing work- G8 Muskoka Initiative, H4+, FP2020, A

Promise Renewed, Commission on Information and

Accountability (CoIA) and the UN Commission on Life-Saving

Commodities for Women and Children (UNCoLSC)

June 2013

8 Pathfinder country Ministers of Health meet in Dakar to share

best practices and progress, as agreed in Abuja

18


19/19

www.everywomeneverychild.org

dickson: un commission on life-saving commodities for women and children

Documents